Genomics Sells Nearly 30,000 Shares: Investor Signal for Genomics Stocks
A CEO’s large stock sale can spark questions about a company’s trajectory. This guide breaks down what genomics sells...
An overview of situations where market-cap weighted benchmarks are appropriate and practical tips for effective performance comparison.
28,264 articlesA CEO’s large stock sale can spark questions about a company’s trajectory. This guide breaks down what genomics sells...
Rigetti Computing just landed $100 million in CHIPS Act funding. This article breaks down what that means for the com...
An insider sold 50,000 shares of Hinge Health, prompting questions about the stock’s outlook. This guide breaks down ...
When a company's CEO sells 31,000 shares worth roughly $1.41 million, it sparks questions for investors. This guide e...
Two popular tech ETFs sit on opposite ends of the spectrum: a broad technology exposure semiconductor approach with V...
A biotech CEO just bought a sizable chunk of his company’s stock. That move sparks questions about conviction, risk, ...
When a Lincoln Educational director sold a sizable block of shares, investors took note. This article breaks down the...
Biote's Q1 2026 earnings call reveals critical insights into revenue growth, margins, and a promising pipeline. This ...
Investing in early-stage biotech requires a steady playbook. This article breaks down Lantern Pharma (LTRN) in 2025, ...
A market dip can feel like a fork in the road. This article uses history and concrete steps to show whether you shoul...
A Life360 board director recently sold several thousand shares after exercising options, timing that coincides with a...
SOXL plunged more than 23% in a single session, underscoring the heavy cost of triple-leverage ETFs. The move compare...